Last reviewed · How we verify

FMX103 1.5% — Competitive Intelligence Brief

FMX103 1.5% (FMX103 1.5%) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic with anti-inflammatory properties. Area: Dermatology.

phase 3 Topical antibiotic with anti-inflammatory properties Bacterial protein synthesis (30S ribosomal subunit); inflammatory mediators Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

FMX103 1.5% (FMX103 1.5%) — Vyne Therapeutics Inc.. FMX103 is a topical minocycline formulation that reduces bacterial colonization and inflammatory mediators in the skin.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FMX103 1.5% TARGET FMX103 1.5% Vyne Therapeutics Inc. phase 3 Topical antibiotic with anti-inflammatory properties Bacterial protein synthesis (30S ribosomal subunit); inflammatory mediators

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic with anti-inflammatory properties class)

  1. Vyne Therapeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FMX103 1.5% — Competitive Intelligence Brief. https://druglandscape.com/ci/fmx103-1-5. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: